Charles Zhu
Stock Analyst at LifeSci Capital
(2.71)
# 2,011
Out of 4,944 analysts
25
Total ratings
50%
Success rate
20.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $13.07 | +68.32% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.56 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $6.76 | +18.34% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.47 | +716.33% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $63.76 | -24.72% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $76.67 | -26.96% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $3.07 | +616.61% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $11.56 | +125.01% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $23.62 | +35.51% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $13.01 | +7.61% | 2 | May 5, 2022 |
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $13.07
Upside: +68.32%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $6.76
Upside: +18.34%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.47
Upside: +716.33%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $63.76
Upside: -24.72%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $76.67
Upside: -26.96%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $3.07
Upside: +616.61%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $11.56
Upside: +125.01%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $23.62
Upside: +35.51%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $13.01
Upside: +7.61%